Combined Lung Transfer of NO and CO in Patients Receiving Methotrexate or Bleomycin Therapy Compared to Normal Subjects

Table 3

CO and NO lung transfers’ results in the three studied groups.

	𝑁 Group	MTX group	BLM group	𝑃
TLCO (%PV)	88.1±4.5	70.6±1.7	67.2±4.9	0.002 MTX versus N and 0.001 BLM versus N
TLNO (%PV)	90.9±1.8	66.3±1.7	66.1±4.2	<0.0001 MTX versus N and <0.0001 BLM versus N
VA (%PV)	97.9±4.2	87.5±3.2	92.9±4.2	NS
KCO (%PV)	95.4±1.9	87.0±3.6	75.2±4.7	0.02 BLM versus MTX, <0.0001 BLM versus N, and 0.05 MTX versus N
VI (%PV)	113±2.7	95.9±3.7	97.3±5.3	0.05 MTX versus N, 0.02 BLM versus MTX, and <0.0001 BLM versus N
TLCO/VI (VI%PV)	0.27±0.02	0.21±0.02	0.25±0.02	0.02 MTX versus N
Dm (%PV)	91.0±1.8	66.3±1.7	67.0±4.0	<0.0001 MTX versus N and <0.0001 BLM versus N
Vc (%PV)	90.7±2.1	70.4±2.2	68.3±5.1	<0.0001 MTX versus N and <0.0001 BLM versus N
TLNO/TLCO	4.60±0.04	4.77±0.07	5.14±0.16	<0.0001 BLM versus N and 0.007 BLM versus MTX

Values are given by mean ± standard error. 𝑃 is calculated by ANOVA. NS: not significant. %PV: percentage of predicted value.